title: Bevacizumab and relapsed ovarian cancer: too many serious and life-threatening adverse effects.
abstract: No proven increase in overall survival when bevacizumab is added to carboplatin and gemcitabine, but significant, sometimes fatal additional adverse effects.
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab